Med2Date — Clinical Guidelines
Home Family Medicine Disorders of the Prostate

Disorders of the Prostate

Last updated 1 Jun 2026 · Urology

📋 Key Information Summary

📋
  • Prostatitis affects up to 15% of Australian men at some point in life; the NIH classification divides it into acute bacterial (Category I), chronic bacterial (Category II), chronic prostatitis/chronic pelvic pain syndrome (Category III), and asymptomatic inflammatory (Category IV).
  • Acute bacterial prostatitis is a urological emergency — high fever, rigors, perineal pain, and a tender boggy prostate on DRE. Rectal prostate massage is CONTRAINDICATED in suspected acute prostatitis.
  • First-line antibiotics for acute bacterial prostatitis are oral ciprofloxacin 500 mg BD for 28 days or trimethoprim 300 mg daily for 28 days; IV agents (gentamicin + ampicillin or ceftriaxone) are required for severe sepsis.
  • Benign prostatic hyperplasia (BPH) is the most common prostate condition; prevalence rises from ~50% at age 50 to >80% at age 80. It causes lower urinary tract symptoms (LUTS) — nocturia, hesitancy, weak stream, frequency.
  • First-line medical therapy for moderate–severe LUTS is an alpha-adrenoceptor blocker (tamsulosin 400 µg daily or silodosin 8 mg daily); 5-alpha reductase inhibitors (dutasteride 0.5 mg daily or finasteride 5 mg daily) are added for significantly enlarged prostates (>40 mL).
  • Prostate-specific antigen (PSA) is the primary screening biomarker but has significant limitations — sensitivity ~70%, specificity ~30% at a cut-off of 4.0 ng/mL. Age-specific reference ranges and PSA density/velocity improve interpretation.
  • The Prostate Cancer Foundation of Australia (PCFA) recommends informed, shared decision-making for PSA testing from age 50 (or 40 with family history); population-based screening is not recommended.
  • The ISUP Grade Groups (1–5) have replaced the traditional Gleason scoring system for reporting; Grade Group 1 (Gleason ≤6) = low risk, Grade Group 4–5 (Gleason 8–10) = very high risk.
  • Localised prostate cancer management ranges from active surveillance (Grade Group 1, low-volume) to radical prostatectomy or radiotherapy (intermediate/high risk); metastatic disease is managed with androgen deprivation therapy (ADT) ± novel hormonal agents.
  • 5-alpha reductase inhibitors reduce PSA by approximately 50% — always double the measured PSA when interpreting results in men taking finasteride or dutasteride.
  • Aboriginal and Torres Strait Islander men have higher prostate cancer mortality despite similar incidence, driven by later stage at diagnosis and reduced access to specialist care. Culturally safe, community-based screening and education programmes are essential.
  • Red flags requiring urgent urology referral: suspected acute prostatitis with sepsis, suspected prostate cancer (hard nodular prostate, elevated PSA), urinary retention, recurrent haematuria, or renal impairment secondary to obstruction.

Introduction & Australian Epidemiology

Prostate disorders encompass a broad spectrum of conditions — from the acute infective emergencies of bacterial prostatitis, through the highly prevalent benign prostatic hyperplasia (BPH) causing lower urinary tract symptoms (LUTS), to prostate cancer, which is the most commonly diagnosed non-skin cancer in Australian men. These conditions frequently co-exist, share overlapping symptom profiles, and often present to general practitioners as the first point of contact within the Australian healthcare system.

In Australia, prostate cancer accounts for approximately 25,000 new diagnoses annually and is the second leading cause of cancer-related death in men, with roughly 3,500 deaths per year (Australian Institute of Health and Welfare, 2024). BPH affects an estimated 2.4 million Australian men, with prevalence increasing sharply with age. Prostatitis remains one of the most common urological outpatient diagnoses in men under 50, responsible for approximately 2 million GP consultations per year nationally.

⚠️
Important: Prostate conditions may coexist. A man with known BPH can develop acute prostatitis or harbour incidental prostate cancer. Serial PSA monitoring and clinical vigilance are required.

This article provides a structured, evidence-based approach to the diagnosis and management of prostatitis (acute and chronic), benign prostatic obstruction, and prostate cancer — including PSA interpretation, Gleason grading, staging, and Australian-specific management pathways — in accordance with Therapeutic Guidelines, RACGP guidance, Urological Society of Australia and New Zealand (USANZ) recommendations, and current PBS listings.

Prostatitis — Acute Bacterial Prostatitis (NIH Category I)

Acute bacterial prostatitis (ABP) is a sudden bacterial infection of the prostate gland presenting with systemic features of infection and urinary symptoms. It is classified as NIH Category I prostatitis and represents a true urological emergency when complicated by sepsis or urinary retention.

Clinical Presentation

  • Acute onset of high fever (>38.5°C), rigors, and malaise
  • Perineal, suprapubic, or low back pain — often severe
  • Dysuria, frequency, urgency, and obstructive voiding symptoms
  • Systemic toxicity — may progress to sepsis or septic shock
  • On DRE: prostate is exquisitely tender, warm, boggy, and swollen
🚨
NEVER perform prostatic massage in suspected acute prostatitis. This risks bacteraemia and worsening sepsis. Diagnosis is clinical and supported by midstream urine (MSU) culture.

Aetiology

The most common causative organism is Escherichia coli (approximately 80%), followed by other Enterobacteriaceae (Klebsiella, Proteus), Enterococcus faecalis, and Pseudomonas aeruginosa. Community-acquired UTI pathogens predominate. In men who have sex with men (MSM), sexually transmitted organisms including Neisseria gonorrhoeae and Chlamydia trachomatis should also be considered.

Diagnosis

Essential Midstream urine (MSU) culture and sensitivity Pre-treatment specimen — prior to commencing antibiotics. Identify organism and sensitivities. MBS Item 69315.
Essential Blood cultures (if febrile/septic) Two sets from separate venepuncture sites before antibiotic administration.
Available FBC, CRP, UEC, lactate Assess severity of systemic inflammatory response. Leucocytosis, rising CRP, acute kidney injury may indicate complications.
Referral Transrectal ultrasound (TRUS) or MRI pelvis If prostatic abscess suspected — persistent fever >48 h despite appropriate antibiotics, fluctuant prostate, failure to improve.
Available STI screening (NAAT for gonorrhoea/chlamydia) In sexually active men, especially MSM. First-void urine NAAT. MBS Item 69384.

Chronic Prostatitis & Chronic Pelvic Pain Syndrome

NIH Category II — Chronic Bacterial Prostatitis

Chronic bacterial prostatitis (CBP) is characterised by recurrent urinary tract infections with the same organism, with symptoms that are often less dramatic than ABP. Patients present with relapsing UTIs, perineal discomfort, and post-ejaculatory pain, but typically without systemic features.

  • Recurrent UTIs (≥3 episodes per year) with the same uropathogen
  • Symptoms may include dull perineal or pelvic pain, post-ejaculatory discomfort, and mild LUTS
  • Diagnosis confirmed by the Meares-Stamey 4-glass test or the simpler 2-glass pre- and post-massage test (PPMT)
  • Expressed prostatic secretion (EPS) or post-massage urine shows >10 WBC/HPF and/or positive culture

NIH Category III — Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

CP/CPPS is the most common form of prostatitis (90–95% of cases) and is defined by genitourinary pain lasting >3 months in the absence of a proven bacterial infection. It substantially impacts quality of life, with depression and anxiety rates up to three times higher than the general male population.

Type IIIa
Inflammatory CPPS
White blood cells present in EPS/post-massage urine but cultures are negative. Suggests an inflammatory non-bacterial aetiology.
Setting: GP with urology follow-up
Type IIIb
Non-inflammatory CPPS
No WBC in EPS/post-massage urine and negative cultures. Neuromuscular, myofascial, and psychological factors predominant.
Setting: Multidisciplinary — GP, urology, physiotherapy, psychology

NIH Chronic Prostatitis Symptom Index (NIH-CPSI)

The NIH-CPSI is a validated 9-item questionnaire assessing pain (location, severity, frequency), urinary symptoms, and quality of life impact. Scores range from 0–43: mild (0–9), moderate (10–18), severe (19–43). It should be administered at baseline and used to monitor treatment response.

Management of CP/CPPS

Management is multimodal and symptom-driven. There is no single curative therapy. A stepped approach is recommended:

1
Education & Lifestyle
Reassurance, explanation of condition, stress reduction, pelvic floor physiotherapy, avoidance of caffeine/alcohol/spicy foods, regular exercise.
2
Pharmacotherapy — Alpha blockers
Tamsulosin 400 µg PO daily or alfuzosin 10 mg SR PO daily — especially if voiding symptoms present. Trial for 4–6 weeks minimum.
3
Anti-inflammatory & Analgesic
NSAIDs (e.g., naproxen 250–500 mg BD), paracetamol, or low-dose amitriptyline 10–25 mg nocte for neuropathic pain component.
4
Empirical Antibiotic Trial
A 2–4 week trial of fluoroquinolone or trimethoprim may be considered in IIIa; discontinue if no response. Not recommended for IIIb.
5
Multidisciplinary Referral
Urology, pelvic floor physiotherapy, psychology (CBT for chronic pain), pain management clinic for refractory cases.

Benign Prostatic Obstruction (BPO/BPH) & Lower Urinary Tract Symptoms (LUTS)

Benign prostatic hyperplasia (BPH) refers to the histological proliferation of glandular and stromal tissue in the transition zone of the prostate. When this expansion causes bladder outlet obstruction, it is termed benign prostatic obstruction (BPO). BPH is the most common cause of LUTS in men over 50 and is present in approximately 50% of men at age 50 and over 80% by age 80.

Symptom Classification (ICS Standardisation)

Symptom Type Examples Mechanism
Storage (irritative) Frequency, urgency, nocturia, urge incontinence Detrusor overactivity secondary to obstruction
Voiding (obstructive) Hesitancy, weak stream, intermittency, straining, terminal dribbling, incomplete emptying Bladder outlet obstruction from prostatic enlargement
Post-micturition Post-void dribbling, sensation of incomplete emptying Residual urine in prostatic urethra

Assessment Tools

The International Prostate Symptom Score (IPSS) is the gold-standard validated questionnaire (7 symptom questions + 1 quality-of-life question; score 0–35):

Mild
IPSS 0–7
Minimal impact on quality of life. Watchful waiting with lifestyle advice.
Setting: GP review annually
Moderate
IPSS 8–19
Moderate bother. Consider medical therapy — alpha-blockers first-line.
Setting: GP with lifestyle ± pharmacotherapy
Severe
IPSS 20–35
Major impact on daily life. Combination medical therapy or surgical referral.
Setting: Urology referral for assessment

Initial Assessment (GP)

Essential IPSS questionnaire Baseline and serial monitoring. Available freely from USANZ/RACGP resources.
Essential Digital rectal examination (DRE) Assess prostate size, consistency, symmetry, nodules. A smooth, rubbery, symmetrically enlarged prostate is typical of BPH.
Essential Urinalysis (dipstick ± MSU) Exclude UTI, haematuria. MBS Item 69315 for microscopy and culture.
Essential Serum creatinine and eGFR Assess renal function — chronic retention can cause obstructive nephropathy.
Available PSA Recommended before starting 5-ARI therapy (baseline) and if prostate cancer suspected. MBS Item 66655.
Referral Post-void residual volume (bladder scan or ultrasound) If incomplete emptying suspected, recurrent infections, or prior to surgery. PVR >300 mL is significant.
Referral Uroflowmetry Maximal flow rate (Qmax) <10 mL/s suggests obstruction. Performed in urology clinic.

Red Flags Requiring Urgent Urology Referral

🚨
  • Acute urinary retention (AUR) — painful, palpable bladder, unable to pass urine → emergency catheterisation
  • Recurrent UTIs (≥3/year) in the setting of BPH
  • Macroscopic haematuria attributable to prostate
  • Renal impairment secondary to chronic urinary retention
  • Bladder calculi
  • Suspected prostate cancer (hard nodule, asymmetry on DRE, elevated PSA)

Management of BPH/LUTS

Non-Pharmacological (All Severities)

  • Reduce evening fluid intake to manage nocturia
  • Limit caffeine and alcohol (bladder irritants)
  • Double-voiding technique
  • Review medications — diuretics, anticholinergics, opioids, decongestants may worsen LUTS
  • Bladder training for urgency

Pharmacological Management

💊
Tamsulosin
Flomaxtra® · Generic · Alpha-1A adrenoceptor antagonist
Adult dose 400 µg PO once daily (after breakfast or main meal)
Paediatric dose Not indicated in children
Renal adjustment No adjustment required for eGFR >10 mL/min
Hepatic adjustment Use with caution in severe hepatic impairment (Child-Pugh C)
Key counselling Warn about intraoperative floppy iris syndrome (IFIS) if cataract surgery planned. First-dose hypotension uncommon but advise evening first dose.
PBS status ✔ PBS General Benefit
💊
Silodosin
Silodyx® · Selective alpha-1A adrenoceptor antagonist
Adult dose 8 mg PO once daily with food
Renal adjustment Contraindicated if eGFR <30 mL/min (CrCl <30 mL/min)
Key counselling Highly selective — less ejaculatory dysfunction than tamsulosin. Retrograde ejaculation occurs in ~28%. Contraindicated with strong CYP3A4 inhibitors.
PBS status ⚠ PBS Authority Required
💊
Dutasteride
Avodart® · Generic · 5-alpha reductase inhibitor (type I and II)
Adult dose 0.5 mg PO once daily
Onset 3–6 months for full effect (prostate volume reduction)
Key counselling Halves PSA — multiply result by 2 for cancer screening interpretation. Avoid handling by pregnant women (teratogenic). May cause erectile dysfunction and decreased libido (~5%).
PBS status ✔ PBS General Benefit
💊
Finasteride
Proscar® · Generic · 5-alpha reductase inhibitor (type II)
Adult dose 5 mg PO once daily (BPH dose; note: 1 mg for alopecia)
Renal adjustment No adjustment required
Key counselling Same PSA-halving effect as dutasteride. Sexual adverse effects in ~5%. No handling by pregnant women.
PBS status ✔ PBS General Benefit
💊
Mirabegron
Betmiga® · Beta-3 adrenoceptor agonist
Adult dose 50 mg PO once daily (25 mg if severe renal impairment or moderate hepatic impairment)
Indication Predominant storage symptoms (urgency, frequency) not responding to alpha-blocker alone
Key counselling Monitor blood pressure — can increase BP by ~1–3 mmHg. Alternative to antimuscarinics with less risk of urinary retention.
PBS status ⚠ PBS Authority Required

Combination Therapy

For men with moderate–severe LUTS and a significantly enlarged prostate (>40 mL or PSA >1.5 ng/mL), combination therapy with an alpha-blocker + 5-alpha reductase inhibitor is recommended. The landmark MTOPS and CombAT trials demonstrated superior symptom improvement and reduced risk of AUR and BPH-related surgery compared with either agent alone. Combination therapy should be continued long-term if benefit is sustained.

Surgical Options (Urology Referral)

Procedure Indication Notes
TURP (transurethral resection of prostate) Gold standard for moderate–severe LUTS refractory to medical therapy Prostate 30–80 mL. Risk of TUR syndrome, bleeding, retrograde ejaculation (~65%), erectile dysfunction (~10%).
Holmium laser enucleation (HoLEP) Large prostates (>80 mL), any size Less bleeding, shorter catheter time. Requires specialist expertise. Increasing availability in major centres.
UroLift® (prostatic urethral lift) Mild–moderate LUTS, prostate 30–80 mL, no median lobe Minimally invasive, day procedure, preserves ejaculatory function. PBS-reimbursed under specific criteria.
Prostatic artery embolisation (PAE) High surgical risk, large prostates, catheter-dependent Interventional radiology. Emerging evidence. Limited availability in regional Australia.

Prostate Cancer — PSA & Clinical Features

Prostate cancer is the most commonly diagnosed cancer in Australian men, with a lifetime risk of approximately 1 in 6. The majority are adenocarcinomas arising from the peripheral zone. Early-stage disease is often asymptomatic; symptoms typically indicate locally advanced or metastatic disease.

Prostate-Specific Antigen (PSA)

PSA is a serine protease produced by prostatic epithelial cells. While elevated levels may indicate prostate cancer, PSA is not cancer-specific — it is also elevated in BPH, prostatitis, after DRE, post-ejaculation, and after urinary catheterisation.

PSA Level (ng/mL) Approximate Cancer Risk Recommended Action
< 3.0 ~5% Reassure. Repeat in 2–4 years (or as clinically indicated)
3.0–5.9 ~15–25% Consider age-specific ranges, PSA density, free/total PSA ratio. Discuss referral to urologist.
6.0–9.9 ~30–40% Refer to urologist. Multiparametric MRI (mpMRI) prior to biopsy (PI-RADS scoring).
10.0–19.9 ~50–65% Urgent urology referral. mpMRI + systematic ± targeted biopsy.
≥ 20.0 ~75–80% Urgent urology referral. High probability of significant disease. Consider staging CT/bone scan.

Factors Affecting PSA

Increase PSA Decrease PSA
BPH, prostatitis, urinary retention, recent DRE, ejaculation within 48 h, urinary catheterisation, prostate biopsy (<6 weeks), vigorous cycling/riding 5-alpha reductase inhibitors (reduce by ~50%), obesity (dilutional), certain herbal supplements (saw palmetto — minimal effect)
⚠️
5-ARI Adjustment: In men taking dutasteride or finasteride for BPH, multiply the measured PSA by 2 to estimate the true value for prostate cancer screening. A PSA that fails to drop by 50% after 6–12 months of 5-ARI therapy raises suspicion for prostate cancer and warrants urological assessment.

PCFA Screening Recommendations

The Prostate Cancer Foundation of Australia (PCFA) and the RACGP recommend an informed decision-making approach to PSA testing, rather than population-based screening:

  • From age 50 (or 45 with strong family history, or 40 with very strong family history — ≥2 first-degree relatives diagnosed <60 years)
  • Discuss the benefits (early detection of aggressive cancer) and harms (overdiagnosis, overtreatment, false positives) of PSA testing
  • If initial PSA <3.0 ng/mL with normal DRE, retest every 2–4 years based on risk factors
  • For men with >10 years life expectancy, regular screening may be continued to age 70–75
  • For men with <10 years life expectancy, PSA screening is generally not recommended

Clinical Features of Prostate Cancer

Localised prostate cancer is typically asymptomatic. Symptoms arise from locally advanced or metastatic disease:

  • Local symptoms: LUTS (obstructive/irritative), haematuria, haematospermia, erectile dysfunction
  • Locally advanced: Pelvic pain, urinary retention, obstructive uropathy, lower limb oedema (pelvic lymphadenopathy)
  • Metastatic: Bone pain (especially lumbar spine, pelvis, ribs), pathological fractures, spinal cord compression, weight loss, fatigue, anaemia
  • DRE findings: Hard nodular prostate, loss of median sulcus, asymmetry, fixation to adjacent structures — these findings carry a high positive predictive value for malignancy
🚨
Spinal cord compression is a urological-oncological emergency. Presenting features include new bilateral leg weakness, sensory level, urinary retention, or bowel dysfunction in a man with known prostate cancer. Requires immediate MRI spine and urgent oncology/neurosurgery referral.

Gleason Score, ISUP Grade Groups, Staging & Risk Stratification

Gleason Grading & ISUP Grade Groups

The Gleason grading system assigns a score based on the architectural patterns of prostate cancer seen on biopsy (primary pattern + secondary pattern = Gleason score, range 2–10). The International Society of Urological Pathology (ISUP) has since introduced a simplified Grade Group system (1–5) that better correlates with prognosis and is now the standard for reporting in Australian pathology.

ISUP Grade Group Gleason Score Risk Category Clinical Behaviour
1 ≤6 (3+3) Low Indolent. Suitable for active surveillance in most cases.
2 7 (3+4) Favourable intermediate Low-volume disease may be suitable for active surveillance. Otherwise curative treatment recommended.
3 7 (4+3) Unfavourable intermediate Active treatment (surgery or radiotherapy + ADT) generally recommended.
4 8 (4+4 or 3+5 or 5+3) High Aggressive. Curative-intent treatment with multimodal therapy.
5 9–10 (4+5, 5+4, 5+5) Very high Highly aggressive. High risk of metastasis and mortality. Intensified treatment required.

TNM Staging (AJCC 8th Edition)

Stage T N M Description
I T1–T2a N0 M0 Localised, low risk. Organ-confined, non-palpable or ≤½ of one lobe.
II T2b–T2c N0 M0 Localised, intermediate risk. Involves both lobes.
III T3a–T3b N0 M0 Locally advanced. Extracapsular extension (T3a) or seminal vesicle invasion (T3b).
IVA T4 N0 M0 Invades adjacent structures (bladder, rectum, pelvic wall).
IVB Any T Any N M1 Metastatic — regional lymph nodes (M1a), bone (M1b), or visceral (M1c).

Risk Stratification for Localised Disease (D'Amico / NCCN Modified)

Low Risk
Favourable Prognosis
PSA <10, Grade Group 1, T1c–T2a. Active surveillance is the preferred initial strategy.
Setting: Active surveillance with GP and urologist
Intermediate Risk
Moderate Prognosis
PSA 10–20, Grade Group 2–3, T2b–T2c. One or more intermediate-risk factors. Curative treatment recommended.
Setting: Urology MDT — surgery or radiotherapy + short-course ADT
High / Very High Risk
Aggressive Disease
PSA >20, Grade Group 4–5, T3a–T4. High risk of local and distant failure. Multimodal therapy required.
Setting: Urology MDT — radical prostatectomy + extended PLND, or EBRT + long-term ADT ± abiraterone

Staging Investigations

Essential Multiparametric MRI (mpMRI) prostate PI-RADS v2.1 scoring. Preferred prior to first biopsy (PI-RADS ≥3 warrants biopsy). MBS Item 63530.
Essential Transperineal or transrectal prostate biopsy Template transperineal biopsy increasingly preferred (lower infection risk). MRI-targeted + systematic cores. MBS Item 37217.
Available CT abdomen/pelvis For staging intermediate–high risk disease. Assess lymphadenopathy and visceral metastases.
Available Bone scan (Tc-99m MDP) For high-risk disease (PSA >20, Grade Group ≥4, or bone pain). Detects osteoblastic metastases.
Specialist PSMA PET/CT (Ga-68 or F-18) MBS Item 63584 (since July 2022) — for initial staging of intermediate–high risk prostate cancer, biochemical recurrence, and equivocal staging. Superior sensitivity for nodal and distant metastases. Available in major capital cities and expanding regional access.

Prostate Cancer — Management

Active Surveillance

Active surveillance is the preferred management for low-risk prostate cancer (Grade Group 1) and select favourable intermediate-risk disease (Grade Group 2, low volume). It avoids or defers the morbidity of radical treatment while maintaining oncological safety.

Baseline
Confirmatory mpMRI ± repeat biopsy within 12 months. PSA, DRE. Counselling re: eligibility criteria.
Year 1–2
PSA every 3–6 months. DRE every 6–12 months. Repeat mpMRI at 12 months if not yet performed. Repeat biopsy at 12–24 months.
Year 3+
PSA every 6 months. DRE annually. mpMRI every 2–3 years. Biopsy every 3–5 years or if PSA/mpMRI change.
Trigger for reclassification
Upgrade on biopsy (≥Grade Group 2), significant PSA kinetics (PSA-DT <3 years), MRI progression (PI-RADS ≥4), patient preference.

Radical Prostatectomy

Radical prostatectomy (open, laparoscopic, or robotic-assisted) is the standard surgical treatment for localised prostate cancer in men with >10-year life expectancy. Robotic-assisted radical prostatectomy (RARP) is the predominant approach in Australian centres.

  • Indicated for localised disease (T1–T3a), Grade Group 1–5, life expectancy >10 years
  • Extended pelvic lymph node dissection (ePLND) for intermediate–high risk disease
  • Key complications: urinary incontinence (5–20% at 1 year), erectile dysfunction (30–70%, depends on nerve-sparing), anastomotic stricture (<5%)
  • Post-operative PSA should become undetectable (<0.1 ng/mL) within 6 weeks; biochemical recurrence defined as PSA ≥0.2 ng/mL on two consecutive occasions

Radiotherapy

External beam radiotherapy (EBRT) and brachytherapy are curative-intent alternatives to surgery:

  • EBRT (IMRT/VMAT): 74–80 Gy in 37–40 fractions (conventional) or moderate hypofractionation (60 Gy in 20 fractions). Combined with short-course ADT (4–6 months) for intermediate risk, long-course ADT (18–24 months) for high risk.
  • Low-dose rate (LDR) brachytherapy: I-125 seed implant. Suitable for low-risk, select intermediate-risk. Not for large prostates (>60 mL) or significant LUTS.
  • Stereotactic body radiotherapy (SBRT): 35–40 Gy in 5 fractions. Emerging evidence supports use in low–intermediate risk. Increasing availability in Australian centres.
  • Key side effects: radiation proctitis, cystitis, erectile dysfunction (gradual onset over 2–3 years), fatigue

Androgen Deprivation Therapy (ADT)

💊
Leuprorelin (Leuprolide)
Lucrin® · LHRH agonist
Adult dose 22.5 mg SC every 3 months (or 45 mg every 6 months as Lucrin Depot PDS)
Duration 4–6 months (intermediate risk with RT) or 18–24 months (high risk with RT). Lifelong for metastatic disease.
Key counselling Flare phenomenon — first dose may worsen symptoms (bone pain, spinal cord compression risk). Consider concurrent anti-androgen (bicalutamide 50 mg daily) for 2 weeks. Monitor for metabolic syndrome, osteoporosis, hot flushes, mood changes.
PBS status ✔ PBS Authority Required
💊
Goserelin
Zoladex® · LHRH agonist
Adult dose 10.8 mg SC implant every 3 months (or 3.6 mg monthly)
PBS status ✔ PBS Authority Required
💊
Bicalutamide
Cosudex® · Non-steroidal anti-androgen
Adult dose 50 mg PO daily (flare cover) or 150 mg PO daily (monotherapy for locally advanced, not metastatic)
Key counselling Gynaecomastia and breast pain in ~30–50% (dose-related). Hepatotoxicity (rare — monitor LFTs). Flare cover for 2 weeks when starting LHRH agonist.
PBS status ✔ PBS Authority Required

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

For men whose disease progresses despite ADT (castrate testosterone <1.7 nmol/L + rising PSA ± radiological progression), several agents are PBS-listed and have demonstrated survival benefit:

Agent Mechanism Indication Key Monitoring
Abiraterone + prednisolone CYP17 inhibitor mCRPC (pre- or post-chemotherapy). Also newly metastatic castration-sensitive (with ADT). LFTs, K⁺, BP, fluid retention. Take on empty stomach.
Enzalutamide Androgen receptor inhibitor mCRPC (pre- or post-chemotherapy). Also non-metastatic CRPC and metastatic castration-sensitive. Seizure risk (history of seizure = relative contraindication), falls, fatigue, BP.
Docetaxel Taxane chemotherapy mCRPC, or upfront with ADT for high-volume metastatic castration-sensitive disease (CHAARTED/STAMPEDE criteria). FBC before each cycle. Neutropenic sepsis risk — G-CSF support. Neuropathy, fatigue, nail changes.
Cabazitaxel Taxane chemotherapy mCRPC post-docetaxel (and post-enzalutamide/abiraterone). Higher neutropenia risk than docetaxel. Prophylactic G-CSF recommended.
Radium-223 (Xofigo®) Alpha-emitting radiopharmaceutical Symptomatic bone metastases, no visceral disease. Improves overall survival. FBC, bone scan. Limited to 6 cycles. Radiotherapy precautions.
ℹ️
PBS Authority Required: All agents for mCRPC require authority approval via the PBS. Applications are typically made by the treating oncologist/urologist. Some agents (e.g., abiraterone, enzalutamide) now have streamlined authority codes for first-line mCRPC.

Investigations Summary

Investigation Indication MBS Item Availability
PSA Prostate cancer screening, monitoring BPH treatment, post-treatment surveillance 66655 All pathology labs nationwide
MSU culture Prostatitis diagnosis, UTI exclusion in LUTS 69315 All pathology labs
Multiparametric MRI prostate PI-RADS scoring, biopsy planning, active surveillance monitoring 63530 Major radiology centres, expanding to regional
Prostate biopsy (transperineal) Histological confirmation after positive MRI or elevated PSA 37217 Urologist — public and private
PSMA PET/CT Staging (intermediate–high risk), biochemical recurrence, equivocal staging 63584 Capital cities, expanding. Nuclear medicine / PET centres.
Bone scan (Tc-99m) High-risk staging, bone pain assessment 61318 Nuclear medicine departments — widely available
CT abdomen/pelvis Staging — lymph nodes, viscera 56001 All major radiology providers
Free/total PSA ratio PSA 4–10 — help distinguish BPH from cancer (low f/t ratio = higher cancer risk) 66660 Most pathology labs
Urine dipstick / NAAT UTI exclusion, STI screening in prostatitis 69384 (NAAT) All labs, sexual health clinics

Monitoring

Post-Treatment PSA Surveillance (Biochemical Recurrence)

Treatment Target PSA Biochemical Recurrence Definition Monitoring Interval
Radical prostatectomy <0.1 ng/mL (undetectable) PSA ≥0.2 ng/mL on 2 consecutive readings PSA every 3–6 months for 2 years, then every 6–12 months for 5 years, then annually
Radiotherapy (EBRT/brachytherapy) Nadir + 2 ng/mL (Phoenix criteria) PSA rise of ≥2 ng/mL above nadir PSA every 3–6 months for 5 years, then annually
Active surveillance No single target Reclassification on biopsy/MRI PSA every 3–6 months. Biopsy/MRI per protocol (see above)

ADT Monitoring

  • Testosterone levels: confirm castrate level (<1.7 nmol/L) at 1 month and periodically
  • PSA: every 3–6 months. Rising PSA on ADT = possible castration-resistant disease
  • Bone mineral density (DEXA) at baseline and every 2 years — ADT causes osteoporosis
  • Fasting glucose, HbA1c, lipid profile annually — metabolic syndrome risk
  • Blood pressure monitoring
  • Cardiovascular risk assessment — men on ADT have increased risk of CVD events
  • LFTs if on bicalutamide
  • ECG if on enzalutamide (QT assessment not routinely required but be aware)

BPH Treatment Monitoring

  • IPSS re-assessment at 4–6 weeks, then every 6–12 months
  • PSA (if on 5-ARI) — ensure baseline before starting, then interpret adjusted values
  • Renal function (eGFR) if significant post-void residual or chronic retention
  • Blood pressure (if on alpha-blockers)
  • Post-void residual volume if symptoms worsen or infections recur

Special Populations

👴

Elderly (≥75 years)

PSA screening Generally not recommended if life expectancy <10 years. Shared decision-making essential. High rates of indolent disease overdiagnosis.
ADT side effects Exaggerated metabolic effects — higher cardiovascular event rates, accelerated osteoporosis, sarcopenia, and cognitive decline. DEXA and cardiac risk assessment mandatory.
Alpha-blockers Higher risk of orthostatic hypotension, falls. Start low, titrate cautiously. Avoid in those with postural hypotension history. Consider tamsulosin (less hypotension than prazosin/doxazosin).
Surgical fitness Anaesthetic risk assessment (ASA score) before TURP/RARP. Consider less invasive options — UroLift, PAE — for frail patients.
🫘

Renal Impairment

Ciprofloxacin Reduce dose to 250–500 mg BD if eGFR <30 mL/min. Avoid in severe CKD if alternatives available.
Trimethoprim Use with caution in severe CKD — can cause hyperkalaemia. Monitor K⁺ and creatinine.
Gentamicin Dose based on ideal body weight. Extended-interval dosing preferred. Therapeutic drug monitoring (TDM) mandatory — target trough <1 mg/L. Use IBW for dosing calculations.
Obstructive nephropathy Chronic urinary retention from BPH can cause bilateral hydronephrosis and CKD. Urethral catheterisation with monitoring of renal recovery is the first step. Refer to urology urgently.
🫁

Hepatic Impairment

Bicalutamide Hepatotoxicity risk — monitor LFTs at baseline, monthly for first 4 months, then periodically. Avoid in severe hepatic impairment.
Abiraterone Contraindicated in severe hepatic impairment (Child-Pugh C). Reduce dose in moderate impairment (Child-Pugh B). Monitor LFTs every 2 weeks for first 3 months.
Fluoroquinolones Generally safe in hepatic impairment. No dose adjustment required.
👶

Younger Men (<40 years)

Prostatitis Most common prostate condition in this age group. CP/CPPS is more common than bacterial prostatitis. STI screening is important in sexually active younger men.
PSA screening Start at age 40 if ≥2 first-degree relatives diagnosed <60 years. Genetic counselling may be appropriate (BRCA2 carriers have increased prostate cancer risk).
Prostate cancer Rare but tends to be more aggressive when it occurs. Higher Gleason grades at presentation. Consider germline genetic testing.
🛡️

Immunocompromised

Prostatitis Consider atypical and opportunistic organisms in HIV-positive men or those on immunosuppressive therapy. Broader empirical antibiotic coverage may be warranted. Longer treatment courses may be required.
Prostate biopsy Higher infection risk — especially in men with DM on immunosuppression or HIV. Transperineal approach strongly preferred to reduce infective complications. Prophylactic antibiotics as per local protocol.

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Health Considerations
Epidemiology
Aboriginal and Torres Strait Islander men have a similar incidence of prostate cancer to non-Indigenous Australians, but experience significantly higher mortality (age-standardised mortality rate ratio ~1.4×). This disparity is driven by later stage at diagnosis, reduced access to specialist services, and comorbidities.
Late presentation
ATSI men are more likely to present with advanced (stage III/IV) prostate cancer. Contributing factors include lower PSA testing rates, health system distrust, competing health priorities (cardiovascular disease, diabetes, renal disease), and cultural barriers to discussing prostate and sexual health.
Access to specialist care
Remote and very remote communities have limited access to urologists, radiation oncology, and PSMA PET/CT. Patients may need to travel hundreds of kilometres for biopsy, surgery, or radiotherapy. Patient-assisted travel schemes (PATS in SA, IPTAAS in NSW) and Closing the Gap co-payment programmes can assist with costs.
Cultural safety
Prostate examination (DRE) and discussions about urinary/sexual function require particular cultural sensitivity. Male health workers and Aboriginal Community Controlled Health Organisations (ACCHOs) should be engaged. "Men's business" health days incorporating PSA testing have shown success in some communities.
Prostatitis in remote communities
CA-MRSA rates are significantly higher in remote Indigenous communities. If empirical treatment for acute prostatitis fails to respond to standard fluoroquinolones, consider CA-MRSA coverage with TMP-SMX. Urine culture and sensitivity results are critical before finalising therapy. Access to IV antibiotics may be delayed in remote settings — early retrieval should be considered for septic patients.
Comorbidity burden
The high burden of cardiovascular disease, chronic kidney disease, and type 2 diabetes in ATSI men affects prostate disease management. ADT worsens metabolic syndrome and CVD risk — cardiac monitoring is especially important. Renal impairment affects antibiotic choice in prostatitis and may complicate surgical candidacy. All treatment plans must account for the broader health context.
Screening programmes
There is no national ATSI-specific prostate cancer screening programme. PCFA supports opportunistic PSA testing with informed consent through ACCHOs. Integration of PSA discussion into existing chronic disease management plans (715 Health Checks, GP Management Plans — MBS Items 715, 721) is recommended to reduce stigma and improve uptake.

Quick Reference — Empirical Antibiotic Therapy for Prostatitis

Syndrome
First-Line
Duration
Notes
Acute bacterial prostatitis (mild–moderate)
Ciprofloxacin 500 mg PO BD
28 days
Or trimethoprim 300 mg PO daily for 28 days. Adjust per MSU sensitivities.
Acute bacterial prostatitis (severe/sepsis)
Gentamicin 5 mg/kg IV daily + ampicillin 2 g IV QID
Until clinically stable → oral step-down 28 days total
Or ceftriaxone 2 g IV daily. Monitor renal function. Consider CA-MRSA cover if risk factors.
Chronic bacterial prostatitis
Ciprofloxacin 500 mg PO BD
4–6 weeks
Or trimethoprim 300 mg PO daily for 6 weeks. Guided by MSU/EPS culture.
CP/CPPS (empirical trial — Category IIIa)
Ciprofloxacin 500 mg PO BD
2–4 weeks trial only
Discontinue if no improvement. Not recommended for Category IIIb. Combine with alpha-blocker.

📚 References

  1. 1. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236–237.
  2. 2. Nickel JC, Roehrborn CG, O'Leary MP, et al. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol. 2007;178(3):896–901.
  3. 3. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 1999;53(3):473–480.
  4. 4. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–2398. (MTOPS trial)
  5. 5. Prostate Cancer Foundation of Australia (PCFA). PSA Testing and Early Management of Test-Detected Prostate Cancer — Clinical Practice Guidelines. Melbourne: PCFA; 2023.
  6. 6. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244–252.
  7. 7. Australian Institute of Health and Welfare (AIHW). Cancer data in Australia. Cat. no. CAN 122. Canberra: AIHW; 2024.
  8. 8. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer — 2024 Update. Eur Urol. 2024;86(2):148–163.
  9. 9. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2024. Plymouth Meeting, PA: NCCN; 2024.
  10. 10. Sathianathen NJ, Konety BR, Crook J, et al. Landmark trials in prostate cancer from 2020 to 2023. Nat Rev Urol. 2023;20(9):531–545.
  11. 11. Royal Australian College of General Practitioners (RACGP). Guidelines for Preventive Activities in General Practice (Red Book). 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  12. 12. Urological Society of Australia and New Zealand (USANZ). Position Statement on PSA Testing. Sydney: USANZ; 2022.
  13. 13. National Health and Medical Research Council (NHMRC). Clinical Practice Guidelines for the Management of Uncomplicated Urinary Tract Acute Infections. Canberra: NHMRC; 2022.
  14. 14. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. (STAMPEDE trial)
  15. 15. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).